Intelligent Bio Solutions (INBS) Competitors $1.47 -0.01 (-0.68%) As of 01:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INBS vs. NEPH, TMDIF, MODD, NMTC, POCI, CLGN, ECOR, COCH, FEMY, and VVOSShould you be buying Intelligent Bio Solutions stock or one of its competitors? The main competitors of Intelligent Bio Solutions include Nephros (NEPH), Titan Medical (TMDIF), Modular Medical (MODD), NeuroOne Medical Technologies (NMTC), Precision Optics (POCI), CollPlant Biotechnologies (CLGN), electroCore (ECOR), Envoy Medical (COCH), Femasys (FEMY), and Vivos Therapeutics (VVOS). These companies are all part of the "medical equipment" industry. Intelligent Bio Solutions vs. Its Competitors Nephros Titan Medical Modular Medical NeuroOne Medical Technologies Precision Optics CollPlant Biotechnologies electroCore Envoy Medical Femasys Vivos Therapeutics Nephros (NASDAQ:NEPH) and Intelligent Bio Solutions (NASDAQ:INBS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk. Do institutionals & insiders hold more shares of NEPH or INBS? 41.1% of Nephros shares are owned by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are owned by institutional investors. 6.7% of Nephros shares are owned by insiders. Comparatively, 1.5% of Intelligent Bio Solutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, NEPH or INBS? Nephros has higher revenue and earnings than Intelligent Bio Solutions. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNephros$14.16M3.03$70K$0.1233.75Intelligent Bio Solutions$3.11M3.27-$10.16MN/AN/A Which has more volatility and risk, NEPH or INBS? Nephros has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Intelligent Bio Solutions has a beta of 4.59, indicating that its stock price is 359% more volatile than the S&P 500. Is NEPH or INBS more profitable? Nephros has a net margin of 7.95% compared to Intelligent Bio Solutions' net margin of -319.85%. Nephros' return on equity of 14.89% beat Intelligent Bio Solutions' return on equity.Company Net Margins Return on Equity Return on Assets Nephros7.95% 14.89% 11.64% Intelligent Bio Solutions -319.85%-176.55%-93.89% Does the media refer more to NEPH or INBS? In the previous week, Intelligent Bio Solutions had 2 more articles in the media than Nephros. MarketBeat recorded 6 mentions for Intelligent Bio Solutions and 4 mentions for Nephros. Nephros' average media sentiment score of 1.07 beat Intelligent Bio Solutions' score of 0.57 indicating that Nephros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nephros 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intelligent Bio Solutions 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer NEPH or INBS? Nephros currently has a consensus target price of $5.50, suggesting a potential upside of 35.80%. Given Nephros' stronger consensus rating and higher possible upside, research analysts clearly believe Nephros is more favorable than Intelligent Bio Solutions.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nephros 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Intelligent Bio Solutions 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryNephros beats Intelligent Bio Solutions on 11 of the 14 factors compared between the two stocks. Get Intelligent Bio Solutions News Delivered to You Automatically Sign up to receive the latest news and ratings for INBS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INBS vs. The Competition Export to ExcelMetricIntelligent Bio SolutionsMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.16M$7.66B$5.69B$9.81BDividend YieldN/A2.71%4.61%4.07%P/E RatioN/A73.0330.6625.56Price / Sales3.2729.87465.14116.21Price / CashN/A26.7338.2159.48Price / Book0.6218.319.016.14Net Income-$10.16M$243.10M$3.25B$264.98M7 Day Performance-3.29%2.92%4.84%2.75%1 Month Performance-22.63%2.82%6.85%3.15%1 Year Performance36.74%18.55%30.51%25.14% Intelligent Bio Solutions Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INBSIntelligent Bio Solutions0.6035 of 5 stars$1.47-0.7%N/A+31.0%$10.16M$3.11M0.0010News CoverageEarnings ReportNEPHNephros2.4437 of 5 stars$4.49+15.1%$5.50+22.5%+115.1%$41.34M$14.16M37.4230Positive NewsHigh Trading VolumeTMDIFTitan MedicalN/A$0.36+2.9%N/A+895.7%$41.05M$17.63M-0.2950Gap DownMODDModular Medical0.6493 of 5 stars$0.72-3.5%N/A-57.6%$40.63MN/A-1.4220Earnings ReportNMTCNeuroOne Medical Technologies2.6766 of 5 stars$0.74-1.4%$1.45+96.4%+12.0%$37.29M$3.45M-3.3620News CoverageEarnings ReportPOCIPrecision Optics0.7538 of 5 stars$4.77+0.7%N/A-11.6%$36.26M$19.10M-5.3580CLGNCollPlant Biotechnologies2.9047 of 5 stars$2.98+4.6%$11.50+285.9%-41.9%$36.24M$510K-2.4470Upcoming EarningsECORelectroCore2.684 of 5 stars$4.31-6.7%$25.50+491.6%-12.1%$35.04M$25.18M-2.6650High Trading VolumeCOCHEnvoy Medical3.4824 of 5 stars$1.56+1.6%$9.25+494.9%-47.1%$32.93M$220K-1.0934Negative NewsFEMYFemasys2.9761 of 5 stars$0.78-13.2%$7.33+845.7%-30.0%$29.04M$1.63M-0.9030Earnings ReportShort Interest ↑Analyst RevisionVVOSVivos Therapeutics0.8766 of 5 stars$4.58+4.1%$4.82+5.2%+94.5%$25.91M$15.03M-2.65160News CoverageGap Down Related Companies and Tools Related Companies NEPH Competitors TMDIF Competitors MODD Competitors NMTC Competitors POCI Competitors CLGN Competitors ECOR Competitors COCH Competitors FEMY Competitors VVOS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INBS) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intelligent Bio Solutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intelligent Bio Solutions With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access